

# Caterina Lanna

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4064423/publications.pdf>

Version: 2024-02-01

41  
papers

675  
citations

623188

14  
h-index

642321

23  
g-index

42  
all docs

42  
docs citations

42  
times ranked

786  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lactoferrin as Protective Natural Barrier of Respiratory and Intestinal Mucosa against Coronavirus Infection and Inflammation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4903.	1.8	83
2	Lactoferrin Against SARS-CoV-2: In Vitro and In Silico Evidences. <i>Frontiers in Pharmacology</i> , 2021, 12, 666600.	1.6	61
3	Lactoferrin as Antiviral Treatment in COVID-19 Management: Preliminary Evidence. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 10985.	1.2	47
4	Overview of the molecular determinants contributing to the expression of Psoriasis and Psoriatic Arthritis phenotypes. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 13554-13563.	1.6	41
5	Trifarotene: A Current Review and Perspectives in Dermatology. <i>Biomedicines</i> , 2021, 9, 237.	1.4	36
6	Hospitalisations with Hidradenitis Suppurativa: An Increasing Problem That Deserves Closer Attention. <i>Dermatology</i> , 2016, 232, 613-618.	0.9	34
7	Real life experience of apremilast in psoriasis and arthritis psoriatic patients: Preliminary results on metabolic biomarkers. <i>Journal of Dermatology</i> , 2020, 47, 578-582.	0.6	34
8	Predictive role of vitamin A serum concentration in psoriatic patients treated with IL-17 inhibitors to prevent skin and systemic fungal infections. <i>Journal of Pharmacological Sciences</i> , 2020, 144, 52-56.	1.1	29
9	Pharmacogenomics: An Update on Biologics and Small-Molecule Drugs in the Treatment of Psoriasis. <i>Genes</i> , 2021, 12, 1398.	1.0	25
10	Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo. <i>Cell Cycle</i> , 2020, 19, 257-267.	1.3	22
11	Skin immunity and its dysregulation in psoriasis. <i>Cell Cycle</i> , 2019, 18, 2581-2589.	1.3	21
12	Latest Evidence Regarding the Effects of Photosensitive Drugs on the Skin: Pathogenetic Mechanisms and Clinical Manifestations. <i>Pharmaceutics</i> , 2020, 12, 1104.	2.0	17
13	High-Risk Recurrence Basal Cell Carcinoma: Focus on Hedgehog Pathway Inhibitors and Review of the Literature. <i>Chemotherapy</i> , 2020, 65, 2-10.	0.8	17
14	Antifungal Effect of All- <i>trans</i> Retinoic Acid against <i>Aspergillus fumigatus</i> <i>In Vitro</i> and in a Pulmonary Aspergillosis <i>In Vivo</i> Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	16
15	Experimental Pharmacological Management of Psoriasis. <i>Journal of Experimental Pharmacology</i> , 2021, Volume 13, 725-737.	1.5	15
16	Efficacy and safety of adalimumab in difficult-to-treat psoriasis. <i>Dermatologic Therapy</i> , 2020, 33, e13374.	0.8	14
17	The Role of Glutathione-S Transferase in Psoriasis and Associated Comorbidities and the Effect of Dimethyl Fumarate in This Pathway. <i>Frontiers in Medicine</i> , 2022, 9, 760852.	1.2	14
18	Psoriasis in difficult to treat areas: treatment role in improving health-related quality of life and perception of the disease stigma. <i>Journal of Dermatological Treatment</i> , 2022, 33, 531-534.	1.1	12

#	ARTICLE	IF	CITATIONS
19	Patidegib in Dermatology: A Current Review. International Journal of Molecular Sciences, 2021, 22, 10725.	1.8	12
20	<p>Omalizumab for chronic spontaneous urticaria in â€œcomplexâ€•patients: data from real-life clinical practice</p>. Drug Design, Development and Therapy, 2019, Volume 13, 3181-3186.	2.0	10
21	Apremilast as a target therapy for nail psoriasis: a real-life observational study proving its efficacy in restoring the nail unit. Journal of Dermatological Treatment, 2022, 33, 1097-1101.	1.1	10
22	Investigational drugs currently in phase II clinical trials for actinic keratosis. Expert Opinion on Investigational Drugs, 2019, 28, 629-642.	1.9	8
23	&lt;p&gt;Small Molecules, Big Promises: Improvement of Psoriasis Severity and Glucidic Markers with Apremilast: A Case Report&lt;/p&gt;. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 2685-2688.	1.1	8
24	Clinical efficacy and reflectance confocal microscopy monitoring in moderateâ€•severe skin aging treated with a polyvinyl gel containing retinoic and glycolic acid: An assessorâ€•blinded 1â€•month study proofâ€•ofâ€•concept trial. Journal of Cosmetic Dermatology, 2021, 20, 310-315.	0.8	8
25	Is the prevalence of hidradenitis suppurativa being overestimated in Europe? Or is the disease underdiagnosed? <i>Evidence from a nationwide study across Portuguese public hospitals</i>. International Journal of Dermatology, 2017, 56, 1491-1492.	0.5	7
26	One drug and two diseases: A case of multidrugâ€•resistant hidradenitis suppurativa and psoriasis treated with apremilast. Dermatologic Therapy, 2019, 32, e13089.	0.8	7
27	Nails as immuneâ€•privileged sites: A case of disabling Acrodermatitis continua of Hallopeau successfully treated with Apremilast. Dermatologic Therapy, 2019, 32, e12946.	0.8	7
28	Melanocytic lesion in children and adolescents: an Italian observational study. Scientific Reports, 2020, 10, 8594.	1.6	5
29	Coexisting inflammatory skin diseases: Tildrakizumab to control psoriasis and Omalizumab for urticaria. Dermatologic Therapy, 2022, , e15359.	0.8	5
30	Interaction of Pelargonium sidoides Compounds with Lactoferrin and SARS-CoV-2: Insights from Molecular Simulations. International Journal of Environmental Research and Public Health, 2022, 19, 5254.	1.2	5
31	&lt;p&gt;The Effectiveness of a New Topical Formulation Containing GSH-C4 and Hyaluronic Acid in Seborrheic Dermatitis: Preliminary Results of an Exploratory Pilot Study&lt;/p&gt;. Clinical, Cosmetic and Investigational Dermatology, 2019, Volume 12, 881-885.	0.8	4
32	Improving of psychological status and inflammatory biomarkers during omalizumab for chronic spontaneous urticaria. Future Science OA, 2020, 6, FSO618.	0.9	4
33	Skin advanced glycation end products as a diagnostic and monitoring tool among psoriatic patients: how the therapy helps reduce cardiovascular disease risk. International Journal of Dermatology, 2022, 61, 577-581.	0.5	4
34	Early clinical response to 5-fluorouracil 0.5% and salicylic acid 10% topical solution in the treatment of actinic keratoses of the head: an observational study. Journal of Dermatological Treatment, 2022, 33, 2664-2669.	1.1	4
35	Basal cell carcinomas treated with 0.5% 5â€•fluorouracil and 10% salicylic acid topical solution. Dermatologic Therapy, 2019, 32, e12908.	0.8	3
36	A Case of Pincer Nail Successfully Treated with Tazarotene 0.1% Gel. Case Reports in Dermatology, 2020, 12, 114-118.	0.3	3

#	ARTICLE	IF	CITATIONS
37	Effectiveness of a cosmetic device containing a combination of alpha- and beta-hydroxy acids, urea, and thuja for the treatment of seborrheic keratoses. <i>Journal of Cosmetic Dermatology</i> , 2021, , .	0.8	3
38	Dimethylfumarate efficacy and safety in palmoplantar psoriasis patient affected by <scp>hepatitis b</scp> and depression: A case report. <i>Dermatologic Therapy</i> , 2020, 33, e13659.	0.8	3
39	Birt-“Hogg-“Dub-© syndrome, from non-invasive dermatologic assessment to gene testing, molecular and ultrastructural histologic analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e206-e209.	1.3	1
40	Psychological symptoms in dermatologic patients during the COVID-19 lockdown period: a double center experience. <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, 392-393.	0.1	1
41	Unexpected intranasal basal cell carcinoma. <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, 104-105.	0.1	1